(Q38003864)

26 August 2017

title

Anti-vascular endothelial growth factor treatment for retinal vein occlusions (English)

1 reference

26 August 2017

0 references

Peter A Campochiaro

1

1 reference

26 August 2017

publication date

24 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

227 Suppl 1

1 reference

26 August 2017

page(s)

30-35

1 reference

The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study

26 August 2017

cites work

1 reference

Occlusion of the central retinal vessels

21 January 2018

1 reference

Arteriovenous crossing patterns in branch retinal vein occlusion. The Eye Disease Case-Control Study Group.

21 January 2018

1 reference

Retinal and choroidal neovascularization

21 January 2018

1 reference

Ocular neovascularisation and excessive vascular permeability

21 January 2018

1 reference

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

21 January 2018

1 reference

Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator.

21 January 2018

1 reference

Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions

21 January 2018

1 reference

Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion

21 January 2018

1 reference

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study

21 January 2018

1 reference

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study

21 January 2018

1 reference

Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study

21 January 2018

1 reference

Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.

21 January 2018

1 reference

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

21 January 2018

1 reference

Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion

21 January 2018

1 reference

Bevacizumab in retinal vein occlusion-results of a prospective case series

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000337157

1 reference

26 August 2017

1 reference